Syndax Pharmaceuticals Inc. Key Takeaways

Syndax Pharmaceuticals recently provided key updates at the 47th Annual Global Healthcare Conference, highlighting strong clinical progress for Revuforj and Niktimvo and a well-funded balance sheet to support 1L AML and IPF clinical development. Goldman Sachs maintains a Buy rating with a $34 price target.

Key Takeaways

• 1.Syndax is well-funded following a $250M convert financing, with proceeds targeted for growth, pipeline development, and expansion of lead products Revuforj and Niktimvo.
• 2.Management expects Revuforj to achieve a dominant market share (70-80%) in KMT2A-rearranged AML within 1-2 years, with additional upside potential in NPM1 and 1L AML.

Table of Contents

• Key Takeaways
• Valuation/Risks
• Disclosure Appendix

Document Preview

Page 1 of 1

Subscribe for full accessStart Free Trial